These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17639036)

  • 1. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model.
    Santen RJ; Boyd NF; Chlebowski RT; Cummings S; Cuzick J; Dowsett M; Easton D; Forbes JF; Key T; Hankinson SE; Howell A; Ingle J;
    Endocr Relat Cancer; 2007 Jun; 14(2):169-87. PubMed ID: 17639036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
    J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Models for risk assessment and prediction in breast cancer].
    Hu Z; Li X; Feng MH; Chu JJ; Xie W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Oct; 30(10):1073-7. PubMed ID: 20193393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and risk assessment for breast cancer: molecular and clinical aspects.
    Beckmann MW; Bani MR; Fasching PA; Strick R; Lux MP
    Maturitas; 2007 May; 57(1):56-60. PubMed ID: 17386982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose?
    Jacobi CE; de Bock GH; Siegerink B; van Asperen CJ
    Breast Cancer Res Treat; 2009 May; 115(2):381-90. PubMed ID: 18516672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gail model risk factors: impact of adding an extended family history for breast cancer.
    Crispo A; D'Aiuto G; De Marco M; Rinaldo M; Grimaldi M; Capasso I; Amore A; Bosetti C; La Vecchia C; Montella M
    Breast J; 2008; 14(3):221-7. PubMed ID: 18373641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer.
    Vogel VG
    Menopause; 2008; 15(4 Suppl):782-9. PubMed ID: 18596599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.
    Col NF; Chlebowski RT
    Menopause; 2008; 15(4 Suppl):804-9. PubMed ID: 18596602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast-tissue sampling for risk assessment and prevention.
    Fabian CJ; Kimler BF; Mayo MS; Khan SA
    Endocr Relat Cancer; 2005 Jun; 12(2):185-213. PubMed ID: 15947097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention in postmenopausal women.
    Rastogi P
    Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing a family risk assessment clinic for breast cancer.
    Mulsow J; Lee J; Dempsey C; Rothwell J; Geraghty JG
    Breast J; 2009; 15 Suppl 1():S33-8. PubMed ID: 19775328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening and follow-up of the patient at high risk for breast cancer.
    Willey SC; Cocilovo C
    Obstet Gynecol; 2007 Dec; 110(6):1404-16. PubMed ID: 18055740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
    Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM; Moore TE
    Cancer Nurs; 2008; 31(3):182-90. PubMed ID: 18453874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the risk of bone loss associated with breast cancer treatment.
    Hadji P
    Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammographic density: a heritable risk factor for breast cancer.
    Boyd NF; Martin LJ; Rommens JM; Paterson AD; Minkin S; Yaffe MJ; Stone J; Hopper JL
    Methods Mol Biol; 2009; 472():343-60. PubMed ID: 19107441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Breast cancer chemoprevention. Rational, trials results and future].
    Cutuli B; Lesur A; Namer M; Kerbrat P
    Bull Cancer; 2009 May; 96(5):519-30. PubMed ID: 19467983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
    Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A
    J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.